Annual General Meeting of BioNTech SE

June 1, 2022

English Convenience Translation: German language is decisive.

Slide 1: Annual General Meeting of BioNTech SE
Slide 2: Report of the Management Board on Agenda Item 1

Prof. Dr. Ugur Sahin, CEO & Founder

Slide 3: Operating development 2021/Q1 2022 and operating outlook

Ladies and Gentlemen, shareholders and shareholder representatives,

On behalf of my colleagues on the Management Board, I would like to welcome you to the Annual General Meeting of BioNTech. We thank you for joining us today for this virtual event.

Slide 4: Forward-looking statements

Before we begin our report, please be advised that we will be making "forward-looking statements" in this Annual General Meeting.

As described on page 4 of the presentation, these statements are subject to the risks and uncertainties detailed in our filings with the U.S. SEC, including our most recent Annual Report on Form 20-F. These statements, including without limitation those relating to our COVID-19 vaccine revenues as these include figures that are derived from preliminary estimates provided by our partners; our estimated financial results for 2022; the continued global demand for our COVID-19 vaccine; and the planned next steps in our pipeline programs.

Actual results may differ materially from those projected in these statements. All information in this presentation is current as of the date of its preparation and BioNTech assumes no obligation to update such information.

Slide 5: Safety information
Slide 6: Safety information

Please also note that the following two slides provide important indication and safety information regarding our COVID-19 vaccine.

Let me begin by saying a few introductory words.

The COVID-19 pandemic is one of the greatest global health challenges of recent decades. Since its outbreak, science has been in the public spotlight more than ever before. The unprecedented collaboration of scientists across borders has significantly contributed to the ability to manage the pandemic. This close international collaboration will continue to be critical if we are to prevent future global pandemics.

Working with our collaboration partners, we developed a safe and effective COVID-19 vaccine and gained market approval in just a short time and made it globally available. We overcame the challenge of scaling up production to a capacity of three billion doses per year – making it possible for us to help protect well over one billion people.

I am proud of the goals we achieved in 2021. This success has given us the opportunity to embark on a new phase of growth for BioNTech, strongly aligned with our vision.

Slide 7: Our Vision

Since the founding of BioNTech in 2008, we have pursued our vision of developing novel medicines that fully harness the **power of the immune system to fight disease**. Innovative therapeutic approaches against cancer, infectious diseases and other serious illnesses are our focus. With the approval of our mRNA vaccine COMIRNATY, we have ushered in a new era of immunotherapies during this past financial year, bringing us much closer to realizing our vision.

Slide 8: BioNTech Today | A 21st Century Immunotherapy Powerhouse

Where are we today? BioNTech has evolved into a modern immunotherapy powerhouse. Our success is built on three pillars:

First, BioNTech is a **fully integrated biotechnology company**: We possess the entire pharmaceutical value chain under one roof, covering discovery, translational research, clinical development, GMP manufacturing and commercial capabilities.

Second, our **multi-platform, technology agnostic strategy**. We have a powerful innovation engine that covers various emerging technologies with advanced capabilities in mRNA and synthetic biology.

This modular, cross-technology approach has enabled us to build our third pillar – our **diversified pipeline** of more than 16 investigational product candidates in 20 different clinical trials. These include candidates from ten different platforms.

We are building a 21st Century immunotherapy powerhouse with a mission anchored to our strong sense of Global Social Responsibility. We focus on indications with a high unmet medical need, with the potential to make a positive impact on global health. Our goal through this work is to democratize access to cutting-edge medicines, **for a medicine of tomorrow** available for people worldwide.

Slide 9: 2021: Key Highlights of Progress Towards Vision

Our vaccine enabled us to help people worldwide in 2021, thus having a globally significant impact on human health and on the global economy.

Together with our partner Pfizer, we delivered approximately 2.6 billion doses of our COVID-19 vaccines to more than 165 countries as of the end of last year. The **global deployment of our vaccine, COMIRNATY,** has likely saved millions of lives and is allowing people all over the world to find their way back to a more normal way of living. By the end of 2021, as part of our commitment to equitable access to COVID-19 vaccines globally, we provided more than one billion doses - or approximately 40% - of our COVID-19 vaccine supply globally to low- and middle-income countries.

It has also been an **active year for our oncology pipeline**. We expanded and advanced our clinical pipeline extensively with multiple novel oncology platforms entering the clinic. We advanced four new platforms into first-in-human studies. We also initiated four randomized Phase 2 trials, bringing our total randomized Phase 2 trials to five.

We **acquired in multiple assets and forged collaborations** to complement our existing technologies and capabilities. This includes the cell therapy facility we acquired from Kite, as well as a MediGene asset acquisition and discovery collaboration that further expanded our TCR pipeline.

Given the scope of transformation efforts, we have grown our global organization to **more than 3,000 employees** and expanded our footprint to include new offices in the US, Europe and Asia.

With our successful commercialization of COMIRNATY, we achieved **strong financial results** in 2021, with total annual revenues of approximately 19 billion euros and diluted earnings of 39 euros and 63 eurocents per share.

This financial strength will allow us to **advance the development of our immunotherapies** more broadly and rapidly and continue our **global expansion**.

Slide 10: 2021: A Year of Historic Impact

Slide 10, summarizes COMIRNATY's success story. COMIRNATY is the world's first approved mRNA therapy. It was the fastest-developed vaccine development and one of the most successful market launch in medical history.

By the end of 2021, more than one billion people had been vaccinated with COMIRNATY in record time. Our market share at the end of 2021 was approximately 74 percent in the U.S. and 80 percent in Europe.

I am proud, as well as grateful, for the tireless work of so many people in our Company and that of our partners, who have made this success possible.

Our vaccine has been instrumental in preventing millions of serious illnesses and deaths worldwide and has had trillions of dollars of positive impact on the global economy.

Slide 11: 2021: A Year of Transformation and Progress

We also made major progress in other areas of the Company last year:

In oncology, we significantly expanded our clinical pipeline with nine trial starts. We also reported initial positive results from six phase 1 trials.

More than 2,000 colleagues now work in R&D and in GMP manufacturing. This equals more than two-thirds of our workforce. We expanded both departments significantly last year to further advance our pipeline and ensure delivery capability.

We made significant investments in our production capacities for mRNA vaccines and innovative gene and cell therapies for oncology during the past financial year. Both of these are important key technologies for BioNTech. With the acquisition of a U.S. manufacturing facility in Gaithersburg, we now have production facilities for cell therapies on both sides of the Atlantic.

Our global footprint grew with the opening of new offices in Singapore, Shanghai and Turkey.

In Germany, we established our first sales team for COMIRNATY – forming the first important building block for developing our future commercial infrastructure.

Slide 12: Diversity – Important Success Factor

Diversity and an open corporate culture are important success factors and critical to our continuing innovation. BioNTech's history is a powerful example of how different cultures and perspectives enrich the Company and contribute to its success.

The BioNTech team today comprises more than 3,000 employees from over 60 nations worldwide. This past financial year, 1,200 new colleagues joined the group.

Despite the considerable growth of our organization, we strive to maintain our flexibility and speed. This is crucial for innovation, efficiency and identifying new opportunities.

To promote diversity, the Management Board set a target in April 2020 to have women in 25 percent of the first- and second-level managerial positions. Although this target has not yet been achieved on the Management Board or Supervisory Board, women currently represent 51 percent of our total workforce and 43 percent of our second-level management positions.

We are committed to continuously promoting the development of our employees. In addition, we are continuously strengthening our team with specialists to drive scientific innovation and our global growth.

The center of our activities remains in Germany, with seven sites. With 12 subsidiaries, we are now globally positioned.

Slide 13: Global Social Responsibility at Our Core

Global Social Responsibility is at the core of who we are as a company. Our key commitments are summarized on slide 13.

The core of our activities is to enable global access to innovative medicines at an early stage. This means we want to democratize access to innovation. One example of this commitment is our joint pledge with our partner Pfizer to deliver more than two billion doses of our COVID 19 vaccine to low- and middle-income countries by the end of 2022.

Another component of our commitment is the development of new medicines for diseases with high unmet medical need in low-income countries. An example is our plan to combat infectious diseases on the African continent and other regions. This includes programs to develop mRNA vaccines for the prevention and treatment of malaria, tuberculosis and HIV.

We are convinced that producing vaccines locally that meet international standards is the most sustainable way to achieve vaccine equity. We plan to start building a modern mRNA production facility in Africa as early as mid-2022.

As part of this plan, we want to use the recently introduced BioNTainer concept, which provides a safe, flexible and easily scalable method to produce mRNA vaccines. The BioNTainer is a turnkey mRNA manufacturing facility based on shipping containers. The containers are built as clean rooms and are designed and equipped for mRNA production. Our BioNTainers can be transported worldwide by truck, ship or plane, making it possible to manufacture our mRNA vaccines locally according to the needs of each partner country.

Our dedication to social responsibility is also reflected in our commitment to responsible corporate governance, environmental and climate protection, and respect for human rights. We have set specific climate protection targets that meet the requirements of the Science Based Targets Initiative. Our aim is to achieve a 42 percent absolute reduction in our Scope 1 and 2 greenhouse gas emissions by 2030 versus the baseline year of 2021.

We adhere to ethical business practices, including good corporate governance, social and societal responsibility, and sustainability. We have signed the United Nations Global Compact – the world's largest and most important initiative for sustainable and responsible corporate governance. It pursues the goal of initiating change processes in companies and anchoring sustainability strategically, with a focus on the topics of human rights and labor standards, the environment and climate, and corruption prevention.

Slide 14: Multi-platform strategy

I would now like to introduce to you our technology platform, which we have been continuously building and expanding since the Company was founded.

Slide 15: Multi-platform Strategy: Toolbox for Innovation

Slide 15 illustrates the building blocks of our innovation strategy to drive the development of new immunotherapeutic drugs. We have built a toolkit of versatile and modular technologies. Our toolbox includes mRNA vaccines and mRNA therapeutics, gene and personalized T-cell therapies, and next-generation targeted antibody therapeutics and immunomodulators. We continue to advance our technology platforms and have also strengthened it through acquisitions and collaborations.

At the beginning of my presentation, I mentioned our collaboration with Medigene, which we began in February of 2022. This collaboration gives us the opportunity to expand our spectrum of personalized TCR therapies against different targets.

Through the acquisition of PhagoMed, we have secured access to lysine-based precision antibiotics – a powerful new class of drugs to address the challenges posed by multi-drug-resistant bacteria.

And through our collaboration with Crescendo Biologics, we are gaining access to technologies and know-how that strengthen our capabilities in the field of cell therapies and antibodies.

The breadth of our technology platforms is greater than the sum of its parts. We can combine mechanisms of action in a more coordinated and precise manner than with currently available therapies. Our synergistic platform and manufacturing capabilities help us to initiate a paradigm shift towards individualized immunotherapy.

Slide 16: Diversified Product Pipeline

Our multi-platform strategy with unique combination potential has enabled us to develop a broad pipeline of drug candidates that are either currently in clinical trials or will be in the medium term.

Slide 17: Waves of Innovation Propel Us Toward Our Vision

We are building a differentiated pipeline that we believe could usher in a new era of immunotherapy through several waves of innovation. We aim to bring several innovative drugs to market in the next three to five years.

The success of our COVID-19 vaccine has validated and established mRNA as a new class of drugs. We have invested over 15 years of research into our diverse mRNA technologies and have developed different mRNA platforms, each specifically tailored for respective medical applications. We are already working on the second and third generations of our mRNA technologies.

The next wave of innovation includes product candidates in oncology and infectious diseases. In oncology, we are currently working on 16 programs in 20 ongoing clinical trials, including five randomized phase 2 studies. In infectious diseases, we are pursuing one phase 1 program and more than ten preclinical programs. We intend to conduct pivotal studies in the coming years and to bring several new immunotherapies to market. We expect both oncology and infectious diseases to generate substantial growth in the medium term.

In addition to oncology and infectious diseases, we see broader applications for mRNA technology in the treatment of inflammatory, cardiovascular and neurodegenerative diseases, and in regenerative medicine. We have already presented preclinical data of mRNA applications in autoimmune diseases in our January 2021 publication of the journal 'Science'.

We have several active programs that are in the product candidate selection Phase. We believe that the further development of our technologies in these new areas will become another important pillar of our long-term value creation.

Slide 18: 2022: Success Through Further Development of the COVID-19 Vaccine

Let me start on slide 18 with updated information on our COVID-19 vaccine.

Since the first approval of our COVID-19 vaccine, we have delivered nearly 3.4 billion doses of COMIRNATY vaccine to more than 175 countries and regions together with our partner Pfizer. Through this, we have established a strong global market position. The 2022 order backlog for our vaccine at the end of April was approximately 2.4 billion doses.

To further extend our market leadership, we are working rigorously on further innovating and optimizing our COVID-19 vaccine.

Meanwhile, we have introduced a ready-to-use formulation with improved storage conditions.

From the very beginning, we had established a broad clinical trial program to evaluate new indications. This led to a number of label expansions for our COVID-19 vaccine in 2021. For example, for use in children five years and older, for immunosuppressed patients, and for booster vaccinations for ages five years and older.

In May 2022, we presented the first results of our Phase 2/3 study in children aged six months to under five years of age. The study data show that the 3µg dose has a good safety profile and provides high protection to the youngest children against the latest COVID-19 variants. We will submit the data to regulatory agencies in the U.S. and Europe, as well as other agencies worldwide, in a timely manner.

As part of pandemic preparedness, it is important to detect and monitor new virus variants at an early stage. Together with the Company InstaDeep, we have developed an early warning system that analyzes globally available sequencing data and predicts high-risk variants of SARS-CoV-2. This warning system enables us to quickly adapt our vaccine candidates in a data-guided manner.

In order to keep pace with changes in the virus in the future, we have established a comprehensive research and development strategy, which I would like to present to you now.

Slide 19: COVID-19 vaccine: Innovation to stay ahead of the virus

Our strategy is based on three pillars: landscape research, product research, and clinical product development.

As part of our landscape research, we want to understand how the virus evolves within the context of vaccination and natural immunity. We have therefore initiated a broad-based research program to study the immune profile after primary vaccinations, booster vaccinations, and breakthrough infections. From the results, we are drawing theoretical conclusions about potential changes we can make in the vaccine that would ideally allow us to respond to possible new viral variants.

The second pillar is product research. Since the approval of COMIRNATY, we have been conducting intensive product research to adapt our vaccine to potential new variants. We have developed several product candidates for COVID-19 follow-on and next-generation vaccines. These include monovalent omicron-adapted vaccines, bivalent and multivalent vaccines, as well as T-cell boosting approaches and pan-coronavirus vaccine concepts.

In clinical product development, we are investigating new product candidates. We are currently focusing on potential vaccine adaptations to the Omicron variant, which is now dominant worldwide. Our clinical program is investigating the safety, tolerability and immunogenicity of various variant-adapted as well as bivalent vaccine candidates. We expect the results of these studies in the weeks ahead and will discuss the results with the regulatory authorities in a timely manner. Based on the clinical data, the regulatory authorities will determine the further regulatory procedure necessary for the potential approval of an adapted vaccine.

Slide 20: Infectious Diseases: Important Area of Growth

We see medicines for the prevention and treatment of infectious diseases as an important growth area for BioNTech. We are leveraging the expertise we gained through our development of the COVID-19 vaccine and applying it to other infectious diseases.

We focus on diseases with a high unmet medical need. Our goal is to tackle unsolved global health problems that have a major impact on the world's population, particularly in developing countries. These include malaria, tuberculosis and HIV, for example.

The World Health Organization estimates there are approximately 229 million new cases of malaria and over 400,000 deaths annually. In 2019, an estimated ten million people were infected with tuberculosis.

And last but not least, HIV, which affects more than 35 million people worldwide – two-thirds of whom are in Africa.

Our product candidates are based on various mRNA platforms that all share the ability to encode specific antigens of a target pathogen and activate T- and B-cell immune responses to fight it.

Other technologies we will use to treat infectious diseases include ribologicals – which are mRNA-encoded antibacterial agents such as mRNA encoded antibodies or a new class of precision antibiotics called synthetic lysines.

We are leveraging these technologies and our deep knowledge of the human immune system to further expand our pipeline in infectious diseases. Our goal is to shorten the development timeline for new vaccines and therapies using a data-guided development approach and artificial intelligence.

Slide 21: Infectious Disease Pipeline: Expect to Start Four Clinical Trials

Slide 21 presents our infectious diseases pipeline, which we have consistently expanded over the past year.

The mRNA encoded influenza vaccine we out-licensed to Pfizer is already in clinical trial testing. In addition, we plan to bring four mRNA vaccine candidates into clinical development by the end of the year. The programs address herpes simplex virus-2, tuberculosis and malaria, as well as shingles, which is in partnership with Pfizer. In addition, our preclinical infectious disease portfolio includes more than ten other mRNA vaccine and antibacterial drug programs.

Slide 22: Oncology: New Precision Therapies with Scaling Potential

A core priority of BioNTech is to develop immunotherapies for the treatment of cancer.

For many cancers, no effective therapies are available. One reason for this is that each cancer has patient-specific molecular and genetic causes. In addition, cancer cells are constantly changing, which is why resistance to treatment can develop over time. Our goal is to develop individually tailored therapies for each patient to provide a new generation of precision therapeutics for the treatment of solid tumors.

Our patient-centric approach encompasses both classical biopharmaceuticals applicable to different cancer types as well as tailored immunotherapies produced individually for each patient as needed. From the outset, we have developed technologies that allow identified antitumor targets to be matched with the optimal treatment approach or combined with another mechanism of action.

Our drug delivery platforms support scalable manufacturing processes to deliver therapies to a high number of patients. We are developing highly digitized and automated manufacturing technologies and quality-controlled processes that will ensure rapid delivery of tailored therapies in the future.

Slide 23: Oncology Pipeline: Significant Progress and Expansion

Slide 23 shows our extensive oncology pipeline. Our spectrum of product candidates is based on our innovative and multimodal platform strategy, which I have already presented to you. We have development candidates from four therapeutic drug classes. These have the potential to target tumors with complementary mechanisms of action, either by directly targeting tumor cells or by modulating the

immune response against the tumor. Many of our product candidates can be combined with other products in our pipeline or with already approved drugs.

We are developing the majority of our oncology programs in-house. Our financial resources allow us to advance the broad pipeline of drug candidates into later-stage clinical trials.

We expect several clinical milestones in 2022.

Together with our partner Genentech/Roche, we plan to report results from our randomized phase 2 study of the iNeST product candidate autogene Cevumeran in first-line melanoma therapy in combination with the checkpoint inhibitor pembrolizumab.

For our CAR-T cell therapy, BNT211, we have already presented first clinical data from the ongoing phase 1/2a trial and plan to publish further results towards the end of the year.

Two additional phase 1 trial starts are planned in the second half of 2022. A RiboMab program, BNT142, against solid tumors and a FixVac immunotherapy, BNT116, against a form of lung cancer. We are conducting the latter study in collaboration with Regeneron.

Slide 24: Phase 2 Oncology Programs

Finally, I would like to briefly introduce our Phase 2 programs. The product candidates are based on three different technology platforms.

Our BNT111 and BNT113 programs are based on FixVac technology. This involves stimulating the patient's immune system against tumor antigens that are frequently expressed in certain types of cancer.

The FixVac programs BNT111 and BNT113 are in randomized Phase 2 trials. We are investigating BNT111 in refractory or checkpoint inhibitor-resistant melanoma patients. For this program, we have received fast-track and orphan drug designation in the United States.

The second development candidate, BNT113, is being clinically evaluated in HPV-16 positive head and neck tumors.

For both programs, we see the potential to improve patient outcomes in combination with a checkpoint inhibitor.

The second technology platform in Phase 2 testing is iNeST. This is our individualized mRNA immunotherapy targeting tumor-specific neoantigens in cancer patients. We are developing the product candidate autogene Cevumeran in collaboration with Genentech/Roche. As mentioned earlier, we are testing this in a randomized Phase 2 trial as first-line therapy in melanoma patients in combination with pembrolizumab.

A second study is evaluating autogene Cevumeran in colorectal cancer in the adjuvant setting.

BNT311 is a bispecific immunomodulator that we are developing together with our partner Genmab. The term "bispecific" refers to the antibody's ability to bind to two different molecules on tumor cells and immune cells. This product candidate is currently being investigated in a randomized Phase 2 study in patients with non-small cell lung cancer.

Slide 25: Outlook for 2022

Let me conclude by summarizing our strategic priorities for 2022.

Slide 26: Strategic Priorities in 2022

Our product development priorities for the current financial year can be divided into four areas.

First, **the further development of our COVID-19 vaccine**. It is our goal to expand our leading market position in COVID-19 vaccines through further development and product optimizations to address the challenges brought on by new COVID-19 variants and to develop next-generation vaccines.

Second, in the field of **oncology,** we plan to advance our product programs towards market approval. Preparations for the corresponding pivotal studies have started. Furthermore, we expect first results from a randomized Phase 2 trial for the iNeST platform and proof-of-concept data for our CAR-T cell therapy in solid tumors.

Third, we will further expand our **clinical pipeline of vaccine candidates**. We plan to start clinical trials for four infectious disease programs in 2022.

And fourth, we are expanding the application of our mRNA technology into **new therapeutic areas** such as autoimmune diseases, regenerative medicine and cardiovascular diseases.

Next to these product-focused objectives, we intend to deepen and expand our capabilities. To underpin the planned growth, we are continuously investing in the foundation of our Company. We plan to further expand competencies in artificial intelligence and digitalization, which are other important pillars of our growth. We are also investing in the expansion of our development teams, our production infrastructure, and our global presence.

We are in an extraordinary situation. Through the success of our COVID-19 vaccine, we have a unique opportunity to realize our long-term vision and, through our innovation, help shape the medicine of the future. We believe we are well-positioned to seize this opportunity.

In closing, on behalf of my colleagues on the Management Board and on behalf of the Supervisory Board, I would like to take this opportunity to thank all our employees. Without the tireless efforts and exceptional commitment of our teams worldwide, our success would not be possible. I am very grateful to be able to work with such a dedicated and talented group of colleagues and for what we have achieved together.

We would also like to thank you, our shareholders. We greatly value your trust and support in these extraordinary times. Your support helps us, helps the people who can benefit from our medicines, and helps make the world a better place. And we look forward to taking the next steps together in implementing our strategy and achieving our mission.

Thank you for your attention. I will now hand the meeting back to our Meeting Chairman.

Helmut Jeggle, Meeting Chairman:

Thank you very much, Ugur, for your presentation.

I will now hand over to Jens Holstein, the Company's Chief Financial Officer, to present the Management Board's financial report.

Jens Holstein, Chief Financial Officer

Slide 27: Financial development in 2021/Q1 2022 and 2022 financial outlook

Thank you very much, Helmut.

I would also like to warmly welcome everyone to today's Annual General Meeting.

Slide 28: Key Highlights of the 2021 Financial Year (1)

Ladies and gentlemen, dear shareholders, the 2021 financial year was an extraordinary year, which is evident when we look at our key financial highlights. In my report to you today, please note that the financial figures I will be presenting always refer to the BioNTech Group as a whole. BioNTech SE, the Group's parent company, contributes significantly to the Group's development, so that we refrain from discussing its individual performance.

- Our total revenues in the 2021 financial year reached 19.0 billion euros and included 18.8 billion euros of COVID-19 vaccine revenues, exceeding our guidance of 16 to 17 billion euros.
- We closed our 2021 financial year with an operating result of 15.3 billion euros and generated earnings per share on a diluted basis of 39 euros and 63 eurocents.
- We ended the 2021 financial year with 2.1 billion euros of cash and cash deposits as well as trade receivables of around 12.4 billion euros. Trade receivables were mainly derived from our collaboration with Pfizer and arose principally from the contractual settlement process. I will explain the timing effects in more depth in a moment.

Slide 29: Key Highlights of the 2021 Financial Year (2)

Let's take a deeper look into our COVID-19 vaccine commercial revenues and their effect on our gross margin on slide 29 of the presentation.

In the 2021 financial year, we recognized COVID-19 vaccine revenues of 18.8 billion euros.

As a reminder, under our two COVID-19 vaccine collaborations, territories were allocated between us, Pfizer and Fosun Pharma based on marketing and distribution rights. Our COVID-19 vaccine revenues include 14.8 billion euros of revenues related to our share of gross profit from vaccine sales in the collaboration partners' territories, together with a number of sales milestones. These revenues already represent a net figure for BioNTech, which means that we generate a 100 percent gross margin on these revenues. As we have mentioned in the past and discussed in more detail in our annual and consolidated financial statements, our profit share is to a certain extent estimated based on preliminary data shared

with our collaboration partner Pfizer. Any changes in our share of the collaboration partner's gross profit will be recognized prospectively.

Our COVID-19 vaccine revenues in the 2021 financial year comprised 3.0 billion euros in revenues from direct COMIRNATY sales to customers in our territory and 1.0 billion euros in revenues from sales to our collaboration partners.

Together with our collaboration partners, we delivered approximately 2.6 billion COVID-19 vaccine doses in 2021. Our shared goal with Pfizer to deliver approximately 40 percent of our vaccine to low- and middle-income countries, while fulfilling the first orders from high-income countries, has been achieved. For the 2022 financial year, we expect to further increase the share of COVID-19 vaccine doses delivered to low- and middle-income countries where prices are in line with local income levels or at a not-for-profit basis. This shift will impact our estimated COVID-19 vaccine revenues for the 2022 financial year.

The gross margin of our COVID-19 vaccine business for the 2021 financial year was impacted by all three revenue streams listed on this slide. Revenues associated with our share of gross profit from COVID-19 vaccine sales in the collaboration partners' territories and our sales milestones have a gross margin of 100 percent and were the dominant factors in the 2021 financial year. The other two factors affecting our gross margin were revenues generated in our own territory and revenues from product sales to our collaboration partners. These two revenue streams have a lower gross margin and, as a consequence, the mix has a significant influence on the overall gross margin.

Overall, we significantly exceeded our expectations for revenues in the 2021 financial year, which is also reflected in the effect on our gross margin.

Slide 30: Key Highlights of the 2021 Financial Year (3)

As shown on slide 30, we ended our 2021 financial year with 1.7 billion euros in cash and cash equivalents as well as cash deposits in the amount of 0.4 billion euros. The latter were returned to cash and cash equivalents in January and February 2022.

When analyzing our liquidity, we anticipate certain significant balance sheet items that are expected to improve our cash and cash equivalents balance subsequent to the end of the reporting period, based on the date of the respective analysis. Acknowledging that this is only a selection, and that cash outlays need to be considered as a cash-reducing factor, our cash and cash equivalents balance subsequent to the end of the reporting period has been significantly improved by our trade receivables. When I come to our capital allocation framework, I will talk about how we expect to use these funds to finance our growth.

As of December 31, 2021, our trade receivables amounted to approximately 12.4 billion euros. As already mentioned, most of the trade receivables as of December 31, 2021 were due from Pfizer and were mainly due to the contractually agreed settlement process for the gross profit share. Trade receivables included, for example, the gross profit due to BioNTech for the third quarter of 2021, for which the settlement payment was received subsequent to the end of the reporting period in January 2022. The settlement payment from Pfizer for the fourth quarter of 2021 was received in April 2022 and was also included in our trade receivables as of December 31, 2021. Please also keep in mind that the settlement for the profit share of December 2021 for the territory outside the United States will not be paid until July 2022. Of course, there are always certain collection risks with trade receivables. The settlement timing largely explains why the cash position was relatively low at the end of 2021 while trade receivables were relatively high.

Slide 31: Comparison Guidance to Actuals 2021 Financial Year

I will now switch to the comparison between our actual results for the 2021 financial year to the guidance we announced as part of the earnings call held in regards to the third quarter of 2021, as presented here. In the 2021 financial year, we generated 18.8 billion euros in revenues from our COVID-19 vaccine. We exceeded our guidance by about 2 billion euros, caused mainly by two factors: first, we were able to increase the volume of COVID-19 vaccine doses delivered to 2.6 billion doses, exceeding our expectation of up to 2.5 billion doses. And second, we exceeded our expectations in terms of price, as the number of vaccine doses sold to higher-income countries was also higher than expected. Both factors were mainly driven by the high demand for booster vaccines – particularly in Europe and the United States – in response to the Omicron variant emerging in late 2021.

Continuing with our costs and investments in the 2021 financial year.

During the 2021 financial year, we incurred R&D expenses of 950 million euros, in line with our guidance. Approximately 40 percent of these expenses were related to COVID-19 vaccine clinical trials.

Moving to our selling, general and administrative expenses, we recognized 340 million euros in SG&A expenses in the 2021 financial year, compared to the originally anticipated 300 million euros. Expenditures were made to support our rapid and sustainable growth, which included accelerating our internal operating activities and investing in inorganic growth opportunities.

Our capital expenditures amounted to 180 million euros in the 2021 financial year, meeting our guidance. These expenditures included inorganic growth investments, infrastructure investments, and investments in our COVID-19 vaccine production capacity, ensuring our projected production capacities.

Slide 32: FY 2021 Financial Results – Profit or Loss

Let's now take a look at our income statement for the 2021 financial year.

Having already covered our revenues, let me start directly with our cost of sales. Our cost of sales reached 2.9 billion euros in 2021, compared to 59.3 million euros in the comparative period of 2020. This increase resulted from the cost of sales recognized in connection with our COVID-19 vaccine revenues and included the share of gross profit that we owe to our collaboration partner Pfizer based on our own sales in Germany and Turkey.

Research and development expenses amounted to 949.2 million euros in the past financial year, compared to 645.0 million euros in the 2020 financial year. This increase was mainly due to an increase in research and development expenses for the clinical trials of the COVID-19 vaccine program BNT162. Another reason for the increase was higher expenses related to increased headcount, as well as expenses incurred under our share-based payment arrangements.

General and administrative expenses reached 285.8 million euros in 2021, compared to 94.0 million euros in the comparative period of 2020. Similar to the increase in R&D, the increase in general and administrative expenses was mainly due to the increase in headcount and expenses under the share-based payment arrangements. Higher expenses for purchased management consulting and legal services, as well as higher insurance premiums caused by the increased business volume, also contributed to the increase, as did our M&A activities and transactions for business development.

Income taxes were accrued in the amount of 4.8 billion euros for the 2021 financial year, compared with 0.2 billion euros in tax income for the comparative period of 2020.

Net profit for the 2021 financial year reached 10.3 billion euros, compared to 15.2 million euros in the previous financial year.

Our diluted earnings per share in the 2021 financial year were 39 euros and 63 eurocents, compared to 6 eurocents in the 2020 financial year.

Slide 33: Highlights of the First Quarter of 2022

Now, I would like to turn to the first quarter of the current financial year.

We got off to a strong start in the 2022 financial year in the first quarter. Slide 33, summarizes for you our most important financial highlights in the first quarter:

- Our total revenues reported for the first quarter of 2022 reached 6.4 billion euros. This is a record figure for BioNTech and was driven by the aforementioned effect of high order volumes since the end of 2021 in connection with the then-emerging Omicron variant.
- We achieved an operating result of 4.8 billion euros and generated earnings per share on a fully diluted basis of 14 euros and 24 eurocents during the first quarter of 2022.
- The cash and cash equivalents of 6.4 billion euros at the end of the first quarter reflect the delayed receipt of payments just described. The settlement payment received in January 2022 from our collaboration partner for the share of gross profit for Q3 2021 is now reflected in the balance. The gross profit shares from two quarters – Q4 2021 and Q1 2022 – are still outstanding and, due to the contractual settlement process, we will only receive these payments during the second and third quarters of 2022.

Slide 34: Q1 2022 Financial Results – Profit or Loss

Let me now briefly touch on some other key expense and earnings figures from the first quarter of 2022 presented here in the income statement.

With our COVID-19 vaccine sales and the strong start to the 2022 financial year just mentioned, our cost of sales – or COGS – increased to 1.3 billion euros in the first quarter of 2022, compared to 0.2 billion euros in the first quarter of 2021. Cost of sales also included expenses arising from inventory write-offs and expenses incurred for production capacities based on contracts with Contract Manufacturing Organizations.

Research and development expenses in the first quarter of 2022 amounted to 0.3 billion euros, compared to 0.2 billion euros for the comparative prior year period. The increase was mainly due to recognizing costs related to the production of pre-launch Omicron vaccine products as research and development expenses in the period incurred, as well as an increase in headcount. This was offset by the fact that our research and development expenses related to our COVID-19 vaccine program were lower as compared to the prior-year period.

General and administrative expenses reached 90.8 million euros in the first quarter of 2022, compared to 38.9 million euros for the comparative period of 2021. This increase was mainly due to increased expenses for purchased management consulting and legal services as well as an increase in headcount.

Income taxes accrued for the first quarter of 2022 amounted to 1.3 billion euros in tax expenses, compared to 0.5 billion euros in tax expenses for the comparative period of 2021. The derived effective

income tax rate for the first quarter of 2022 was 26.3 percent and is expected to be 28 percent for the full year.

Net profit in the first quarter of 2022 reached 3.7 billion euros, compared to 1.1 billion euros in the comparative period of 2021.

Our diluted earnings per share for the first quarter of 2022 amounted to 14 euros and 24 eurocents, compared to 4 euros and 39 eurocents for the comparative period of 2021.

Slide 35: 2022 Financial Year Guidance

Moving to slide 35, I will present the Company's outlook for the 2022 financial year:

We are reiterating our guidance from January 2022, presented at the J.P. Morgan Healthcare Conference and confirmed with the release of our Q1 financial report of estimated COVID-19 vaccine revenues in the range of 13 to 17 billion euros for the full 2022 financial year. This guidance is based on orders signed by BioNTech and Pfizer of approximately 2.4 billion COVID-19 vaccine doses for the 2022 financial year.

Our financial success in 2021 will allow us to redeploy meaningful investments into our research and development activities, our product pipeline, and our operating business to prepare for our anticipated strong growth in the years ahead. In the 2022 financial year, we plan to spend 1.4 to 1.5 billion euros on research and development, which is almost a 50 percent increase compared to 2021. In addition, we intend to continue to increase these investments in the years ahead. We will continue to accelerate our clinical trial programs in oncology and infectious diseases and expand our organizational and human resource capabilities for our continued and sustainable growth. We estimate general and administrative expenses for the 2022 financial year to be between 450 and 550 million euros, as we plan to support our operating growth by continuing to invest in our enabling functions that support our core business and operating growth, such as IT. Capital expenditures for 2022 financial year are expected to be in the range of 450 million to 550 million euros. For example, we plan to expand our R&D and production facilities and enhance and further invest in our digitalization initiatives. Please note that all ranges reflect current baseline forecasts, excluding potential M&A activities and collaborations.

Finally, we would like to point out that our 2022 full-year tax impact is expected to improve significantly, as we anticipate the estimated annual effective tax rate for the BioNTech Group to decrease from 31.6 percent in the previous year to approximately 28 percent.

Slide 36: Capital Allocation Framework for the 2022 Financial Year

As just described, we plan to make significant investments in the 2022 financial year with the goal of building a modern immunotherapy powerhouse. In this context, I would like to explain the capital allocation shown on slide 36.

Our capital allocation is focused on four key areas:

- First and foremost, research and development: We have proven that our science is game-changing. We also believe that our technologies and science can have an even greater impact on people's health. This is why we intend to continue to expand and accelerate our initiatives to create additional long-term value for our shareholders.
- Secondly: M&A and business development: To support our technologies and digital capabilities, we strive to extend and augment our expertise through synergistic acquisitions and collaborations.

- Thirdly: We are expanding our global footprint in Europe, the US, Asia, and Africa and plan to invest in our manufacturing capacities for key technologies.
- And finally, after such an extraordinary year, we want to ensure that our shareholders participate in our success. We have therefore launched a share repurchase program, which I will talk about in more detail in a moment.

  At today's Annual General Meeting, the Management Board and Supervisory Board are also proposing a special cash dividend of 2.00 euros per ordinary share, including those held in the form of ADSs. This corresponds to an aggregate of 484.2 million euros, based on the ordinary shares outstanding and entitled to a dividend as of the record date being May 30, 2022. You will hear more later in the meeting when Helmut Jeggle explains the dividend proposal in more detail.

Slide 37: Capital Transactions in FY 2021 and during the Period until June 2022

At this point, I would like to report to you on the capital transactions that took place during the 2021 financial year and up until now during the current financial year. These include capital increases from authorized capital, conditional capital, and the use of treasury shares and were carried out, excluding subscription rights. Please note that we have summarized the details on slide 37 and will explain the transactions translated into euros using the exchange rates published by Germany's central bank, as shown in the footnotes to the table. Please also note that when we refer to ADSs, we are referring to American Depositary Shares. Each ADS represents one of our ordinary shares.

In the entire 2021 financial year, we had only one capital transaction involving treasury shares. Through the "at-the-market offering program" introduced at the end of 2020, we can sell ADSs for aggregate gross proceeds of up to 500.0 million dollars. In May 2021, we sold 995,890 ADSs previously held in treasury, representing 0.4 percent of our issued share capital as of the transaction date. The sales were made at the respective stock market price on the relevant trading day and amounted to a total translated amount of 163.6 million euros.

In January 2022, we entered into a new research, development and commercialization collaboration with Pfizer to develop a potential first mRNA-based vaccine for the prevention of shingles. As part of this collaboration, Pfizer agreed to make an equity investment and acquired 497,727 of our ordinary shares (or 0.2 percent of issued share capital) in March 2022 with the registration in the Commercial Register. The issuance was made under the exclusion of subscription rights based on section 4 paragraph 5 (b) of our current Articles of Association by way of the simplified exclusion of subscription rights pursuant to section 186 paragraph3 sentence 4 German Stock Corporation Act (*Aktiengesetz*). By excluding subscription rights, we can implement our financing strategy more effectively in the interests of both the Company and our investors. The collaboration related to the capital transaction was strengthened in the best interest of the Group. The new shares were issued at a price of 266.63 euros, which was even above the price of the listed ADS of 223.50 euros at the time of signing the transaction. Based on the issue volume agreed under the Investment Agreement, the total amount related to the investment is 132.7 million euros.

On March 1, 2022, we exercised our early redemption option and fully redeemed our convertible note with Temasek. The conditions for the redemption – including the issue price and the number of ordinary shares to be issued – were established in the contractual agreements dated June 2020. In April, the early redemption option was exercised by issuing 1,744,392 ordinary shares (or 0.7 percent of the issued ordinary shares) for an aggregate of 100.0 million euros. The conditional capital increase pursuant to section 4 paragraph 7 of our current Articles of Association and the corresponding authorizing resolution of the Annual General Meeting on August 19, 2019 was implemented excluding subscription rights.

Slide 38: Share Repurchase Program

The share repurchase program resolved by the Management Board and the Supervisory Board permits the repurchase of ADSs for a value of up to 1.5 billion dollars over two years. Our intention is to use some or all of the repurchased ADSs to meet pending obligations from share-based compensation agreements.

The first tranche of the repurchase scheme began on May 2, 2022 and has a value of up to 1.0 billion dollars. As shown on slide 38, from May 2 until today, a total of 917,988 ADSs were repurchased at an average price of 151.76 dollars. This equals a total of 139.3 million dollars, representing 0.4 percent of the shares issued as of April 30, 2022.

More information and an overview of the buybacks can be found on our website.

Slide 39: Outlook 2022 and Beyond

In closing my report, I would like to say a few words about our plans for the 2022 financial year.

Slide 39, shows the five key areas we have chosen as our strategic focus in 2022.

As we have just explained in detail, we will continue to invest significantly in the further development of our COVID-19 vaccine program.

This year, we plan to continue rapidly expanding our clinical pipeline and expect results for up to three programs in oncology and infectious diseases.

To support the further expansion of our pipeline, we are currently investing in broadening our global development organization.

In addition, we will continue to drive forward our corporate development. Earlier this year, we announced a number of new collaborations with Pfizer, Regeneron, Medigene, and Crescendo Biologics. We will continue to expand our access to complementary synthetic biology technologies, manufacturing infrastructure, and digital capabilities through potential new partnerships, mergers, acquisitions, and in-licensing, in addition to organic investments.

And finally, we plan to further strengthen our international presence in 2022. This includes the expansion of our teams and capacities in the U.S., Europe, Africa, and Asia. Next to further automating our existing manufacturing facilities in Germany, we will invest in new manufacturing hubs in the U.S. and Asia to support our future mRNA and cell therapy product portfolio. We will also remain actively committed to pandemic preparedness.

This brings us to the end of our report from the Management Board. My sincere thanks for your attention. I will now hand back over to Helmut Jeggle, our Meeting Chairman.

Many thanks.